🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Moderate-to-severe Atopic Dermatitis

A Study to Assess the Impact of Lebrikizumab on Health-Related Well-Being and Control of Skin Manifestations in Participants With Moderate-to-Severe Atopic Dermatitis NCT06815380n/a1 site📍 Aarhus Almirall, S.A. · Tests: No Intervention A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema NCT06807268Phase 347 sites📍 Birmingham📍 North Little Rock📍 San Diego Pfizer · Tests: Abrocitinib, Placebo Treatment and Medical Care of Patients With Moderate-to-severe Atopic Dermatitis - TREATswitzerland NCT05819463n/a9 sites📍 Basel📍 Bern📍 Buochs Swiss Society of Dermatology and Venereology ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis NCT06775860Phase 362 sites📍 Hefei📍 Wuhu📍 Beijing Beijing InnoCare Pharma Tech Co., Ltd. · Tests: ICP-332 Tablets, ICP-332 Placebo Tablets A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participants With Moderate to Severe Atopic Dermatitis NCT07235384Phase 112 sites📍 Woolloongabba📍 Carlton📍 Beijing Zai Lab (Shanghai) Co., Ltd. · Tests: ZL-1503, Placebo, ZL-1503, Placebo Evaluation of the Efficacy and Safety of Oral LW402 Tablets for the Treatment of Patients With Moderate-to-Severe Atopic Dermatitis NCT07370909Phase 31 site📍 Beijing Shanghai Longwood Biopharmaceuticals Co., Ltd. · Tests: LW402, Placebo Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults NCT06988605n/a108 sites📍 Birmingham📍 Phoenix📍 Phoenix Galderma R&D A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis NCT07211542Phase 21 site📍 Guangzhou Guangdong Hengrui Pharmaceutical Co., Ltd · Tests: SHR-1905 Injection, SHR-1905 Injection Blank Preparation Phase II Clinical Study to Evaluate the Efficacy and Safety of LT-002-158 Tablets in Adult Patients With Moderate-to-Severe Atopic Dermatitis NCT07895615Phase 21 site📍 Hangzhou Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. · Tests: LT-002-158, Placebo A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis NCT07690371Phase 320 sites📍 Phoenix📍 North Little Rock📍 Fountain Valley Nektar Therapeutics · Tests: Rezpegaldesleukin, Placebo A Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in Participants With Moderate to Severe Atopic Dermatitis NCT07754786Phase 31 site📍 Guangzhou Innovent Biologics (Suzhou) Co. Ltd. · Tests: Dupilumab Injection, IBI3027 A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema) NCT07355075Phase 2, Phase 31 site📍 Irving Turn Therapeutics · Tests: GX-03, Vehicle A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema NCT07783425Phase 332 sites📍 Phoenix📍 Bryant📍 Huntington Beach Pfizer · Tests: Tilrekimig, Dupilumab, Placebo for Tilrekimig, Placebo for Dupilumab Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies. NCT06899204n/a1 site📍 San Diego Pfizer · Tests: Abrocitinib Digital Mindfulness Meditation in Adolescents With Atopic Dermatitis NCT07746427NA2 sites📍 New York📍 New York Weill Medical College of Cornell University · Tests: Digital App Mindfulness Meditation, Mindfulness Meditation Sheet A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis NCT07558668Phase 114 sites📍 Arkansas City📍 Fremont📍 Plainfield Sitryx Therapeutics Ltd · Tests: SYX-5219 Oral Capsule A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis NCT06311682Phase 372 sites📍 Birmingham📍 North Little Rock📍 Palo Alto LEO Pharma · Tests: Tralokinumab + TCS, Placebo + TCS TREAT NL (TREatment of ATopic Eczema, the Netherlands) Registry: Dutch National Registry for Patients With Moderate-to-severe Atopic Eczema on Photo- or Systemic Therapies NCT03621137n/a1 site📍 Amsterdam Academisch Medisch Centrum - Universiteit van Amsterdam (AM… · Tests: No study-specific intervention Intervention With Tralokinumab in Patients With Moderate-to-severe Atopic Dermatitis With Genital Impact NCT07444801n/a2 sites📍 Augsburg📍 Lübeck University Hospital Schleswig-Holstein · Tests: tralokinumab A Study of BYN-001 in Healthy Adults and in Adults With Moderate to Severe Atopic Dermatitis NCT07746817Phase 11 site📍 Melbourne Bionyra Pharma · Tests: BYN-001, Placebo A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Doses in Participants With Moderate to Severe Atopic Dermatitis NCT07604324Phase 11 site📍 Fukuoka Novartis Pharmaceuticals · Tests: DCY636, Placebo Study of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis NCT06947980Phase 21 site📍 Beijing Keymed Biosciences Co.Ltd · Tests: Placebo Comparator, CM512 Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis NCT07298395Phase 232 sites📍 Birmingham📍 Hot Springs📍 Beverly Hills Enveda Therapeutics · Tests: ENV-294, Placebo A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab NCT06524635Phase 22 sites📍 Sacramento📍 Ann Arbor AbbVie · Tests: Lutikizumab A Phase III Study of GS101 Injection to Dupixent® NCT07386743Phase 31 site📍 Shenyang Jiangsu Genscend Biopharmaceutical Co., Ltd · Tests: GS101 injection, DUPIXENT® A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis NCT07599813Phase 285 sites📍 Birmingham📍 Birmingham📍 Phoenix Apollo Therapeutics Ltd · Tests: Camoteskimab, Placebo IB/IIa Study of MG-K10 in Adolescent Moderately Severe Patients NCT06765005Phase 1, Phase 21 site📍 Hangzhou Shanghai Mabgeek Biotech.Co.Ltd · Tests: MG-K10 A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD) NCT07239947Phase 110 sites📍 Hefei📍 Wuhu📍 Beijing Bambusa Therapeutics · Tests: BBT001, Placebo Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD NCT07441395Phase 21 site📍 South San Francisco Corvus Pharmaceuticals, Inc. · Tests: Soquelitinib, Placebo FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients NCT06564389Phase 15 sites📍 Anaheim📍 San Diego📍 Miami Pfizer · Tests: PF-07832837, Placebo
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy